Akt3 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is an active allosteric Akt inhibitor that specifically targets Akt1, Akt2, and AktIt is being studied in clinical trials for its potential in treating various cancers. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine (CAS 35943-35-2) is a compound known for its ability to inhibit Akt3, a protein associated with cell signaling. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 (CAS 612847-09-3) is a compound known for its inhibition of Akt3, a protein involved in cell signaling pathways. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is a small molecule inhibitor of Akt1, Akt2, and AktIt has been studied in preclinical and clinical trials for its anti-cancer activity. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine, also known as KRX-0401, is an experimental drug that inhibits Akt activation. It has been investigated for its anti-cancer properties, particularly in multiple myeloma and other solid tumors. | ||||||
Akt Inhibitor XIII, Isozyme-Selective, Akti2-1/2 | sc-221231 | 2 mg | $480.00 | 1 | ||
Akt Inhibitor XIII, Isozyme-Selective, Akti2-1/2 is a compound that effectively inhibits Akt3, a key protein involved in cell signaling pathways. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is a potent and selective inhibitor of all three Akt isoforms (Akt1, Akt2, and Akt3). | ||||||
AT7867 | 857531-00-1 | sc-364417 sc-364417A | 10 mg 50 mg | $450.00 $1300.00 | 1 | |
AT7867 is a potent inhibitor of Akt1, Akt2, and Akt3, as well as other kinases. It has been investigated for its anti-cancer properties in preclinical studies. | ||||||
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone | sc-501166 | 5 mg | $540.00 | |||
Ipatasertib is a selective inhibitor of Akt1, Akt2, and AktIt is being explored as a potential therapy for various cancers, including breast cancer. | ||||||